Diabetic ketoacidosis (DKA) is an acute and significant life-threatening complication of
diabetes. The association of sodium-glucose cotransporter-2 inhibitors (SGLT2i) with …

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (gliflozins) represent the most recently
approved class of oral antidiabetic drugs. SGLT-2 overexpression in diabetic patients …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to
be introduced for the treatment of type 2 diabetes mellitus (T2DM). They reduce …

According to the 2021 report of the International Diabetes Federation (IDF), there have been
approximately 573 million cases of type 2 diabetes mellitus (T2DM) among adults, which …

Abstract Sodium-glucose cotransporter 2 (SGLT2) plays a pivotal role in mediating glucose
reabsorption within the renal filtrate, representing a well-known target in type 2 diabetes and …

Heart failure (HF) is a common complication or late-stage manifestation of various heart
diseases. Numerous risk factors and underlying causes may contribute to the occurrence …

Glycans are one of the four fundamental macromolecular components of living matter, and
they are highly regulated in the cell. Their functions are metabolic, structural and modulatory …

This article reviews the most current literature on diabetic ketoacidosis, including how to
make the diagnosis and management. It discusses euglycemic diabetic ketoacidosis and the …

Dapagliflozin, a sodium–glucose co-transporter 2 (SGLT2) inhibitor, is an antidiabetic
medication that reduces blood glucose. Although it is well known that dapagliflozin has …

To investigate the effect of polydatin on glucose transporter, blood glucose homeostasis and
renal injury in streptozotocin (STZ)-induced diabetic rats. The in vitro inhibitory effect of …